What Happened?
Shares of clinical research company IQVIA (NYSE: IQV) jumped 8.4% in the afternoon session after it reported strong first-quarter 2026 financial results that surpassed Wall Street expectations and raised its full-year earnings forecast.
The company announced revenue of $4.15 billion, an 8.4% increase compared to the same period in the previous year, with its adjusted earnings per share coming in at $2.90, both of which were above analyst forecasts. Looking ahead, IQVIA showed confidence by reaffirming its full-year revenue guidance and increasing its outlook for adjusted earnings per share to a new range of $12.65 to $12.95.
Is now the time to buy IQVIA? Access our full analysis report here, it’s free.
What Is The Market Telling Us
IQVIA’s shares are somewhat volatile and have had 11 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 10 months ago when the stock gained 15.9% on the news that the company reported second-quarter financial results that beat Wall Street expectations and raised its full-year profit guidance.
The company announced second-quarter revenue of $4.02 billion, which surpassed analyst estimates of $3.96 billion. Adjusted earnings per share (EPS), a key measure of profitability, came in at $2.81, which was also ahead of the consensus forecast of $2.77.
The strong performance was driven by solid growth across its business segments, with the Technology & Analytics Solutions division seeing an 8.9% revenue increase. Looking ahead, IQVIA updated its full-year 2025 guidance. It slightly raised its forecast for adjusted EPS to a range of $11.75 to $12.05. The company also reaffirmed its full-year revenue projection, expecting between $16.1 billion and $16.3 billion. The positive results and optimistic outlook appeared to boost investor confidence, signaling robust demand for its clinical research and data analytics services.
IQVIA is down 23.8% since the beginning of the year, and at $171.69 per share, it is trading 29.7% below its 52-week high of $244.29 from January 2026. Investors who bought $1,000 worth of IQVIA’s shares 5 years ago would now be looking at only $740.25.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.